Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-09-12
2008-07-22
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200, C514S015800, C514S016700, C424S085100, C530S350000, C530S351000, C930S110000, C930S130000
Reexamination Certificate
active
07402558
ABSTRACT:
The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG or LH, or a bio-analogue thereof, is administered during the follicular phase.
REFERENCES:
patent: 5705478 (1998-01-01), Boime
patent: 6407057 (2002-06-01), Emperaire
patent: 6653286 (2003-11-01), Mannaerts et al.
patent: 2002/0103106 (2002-08-01), Palmer et al.
patent: 0 170 502 (1991-06-01), None
patent: WO-99/13081 (1999-03-01), None
patent: WO-00/50066 (2000-08-01), None
patent: WO-00/67778 (2000-11-01), None
patent: WO-01/54715 (2001-08-01), None
Warne et al, The International Recombinant Human Chorionic Gonadotropin Study Group, Induction of Ovulation in WOrld Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of rhCG and urinary hCG, Fertility and Sterility, Jun. 2001, 75(6): 1111-1118.
Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL and Zeleznik AJ, Ovarian Response in Women to Recombinant Follicle-Stimulating Hormone and Luteinizing Hormone (LH): A Role for LH in the FInal Stages of Follicular Maturation, The Journal of Clinical Endocrinology and Metabolism, 1999, 84(1): 228-232.
David Lindsay Healy et al, “Female Infertility: Causes and Treatment”, The Lancet, Jun. 18, 1994, vol. 343, pp. 1539-1544.
Marco Filicori, “Gonadotropin-Releasing Hormone Analogs in Ovulation Induction: Current Status and Perspectives”, Journal of Clinical Endocrinology and Metabolism, 1996, vol. 81, pp. 2413-2416.
Marco Filicori et al, “Different Gonadotropin and Leuprorelin Ovulation Induction Regimens Markedly Affect Follicular Fluid Hormone Levels and Folliculogenesis”, Fertility and Sterility, Feb. 1996, vol. 65, pp. 387-393.
Stephen G. Hillier et al, “Gonadotrophin Control of Follicular Function”, Hrm Res, 1995, vol. 43, pp. 216-223.
Melissa A. Esposito et al, “Role of Periovulatory Luteinizing Hormone Concentrations During Assisted Reproductive . . . ”, Fertility and Sterility, Mar. 2001, vol. 75, pp. 519-524.
“Recombinant Human Luteinizing Hormone (LH) to Support Recombinant Human Follicle-Stimulating Hormone (FSH)-Induced Follicular . . . ”, Journal of Clinical Endocrinology and Metabolism, 1998, vol. 83, pp. 1507-1514.
M. Filicori et al, “Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome”, The Journal of Clinical Endocrinology and Metabolism, 1999, vol. 84, pp. 2659-2663.
Ioannis E. Messinis, M.D. et al, “The Importance of Human Chorionic Gonadotropin Support of the Corpus Luteum During Human Gonadotropin Therapy in Women with Anovulatory Infertility”, Fertility and Sterility, vol. 50, pp. 31-35.
Z.M. Lei et al, “The Expression of Human Chorionic Gonadotropin/Luteinizing Hormone Receptors in Human Endometrial and Myometrial Blood Vessels”, 1992, vol. 75, pp. 651-659.
Hugh P. J. Bennett et al, “Peptide Hormones and Their Analogues: Distribution, Clearance from the Circulation, and Inactivation in Vivo”, Pharmacological Reviews, 1979, vol. 30, pp. 247-292.
B.M.J.L. Mannaerts et al, “A Randomized Three-Way Cross-Over Study in Healthy Pituitary-Suppressed Women to Compare the Bioavailability of Human Chorionic Gonadotrophin . . .”, Human Reproduction, 1998, vol. 13, pp. 1461-1464.
Wiebe Olijve et al, “Molecular Biology and Biochemistry of Human Recombinant Follicle Stimulating Hormone (Puregon)”, Molecular Human Reproduction, 1996, vol. 2, pp. 371-382.
Tadashi Sugahara et al, “Biosynthesis of a Biologically Active Single Peptide Chain Containing the Human Common α and Chorionic Gonadotropin β Subunits in Tandem”, Medical Sciences, 1995, vol. 92, pp. 2041-2045.
Judith L. Vaitukaitis et al, “A Radioimmunoassay Which Specifically Measures Human Chorionic Gonadotropin in the Presence of Human Luteinizing Hormone”, Am. J. Obstet., Gynecol., Jul. 15, 1972, vol. 113, pp. 751-758.
“Radioimmunoassay of Human Choriogonadotropin”, Clinical Chemistry, 1985, col. 31, pp. 1749-1754.
Lee Tyrey, “Human Chorionic Gonadotropin Assays and Their Uses”, Obstetrics and Gynecology Clinics of North America, Sep. 1988, vol. 15, pp. 457-475.
Michael W. Sullivan et al, “Ovarian Responses in Women to Recombinant Follicle-Stimulating Hormone and Luteinizing Hormone (LH): A Role for LH in the Final Stages of Follicular Maturation”, Journal of Clinical Endocrinology and Metabolism, 1999, vol. 84, pp. 228-232.
E.Kousta et al, “Successful Induction of Ovulation and Completed Pregnancy Using Recombinant Human Luteinizing hormone and Follicle Stimulating Hormone in a Woman with Kallmann's Syndrome”, Human Reproduction, 1996, vol. 11, pp. 70-71.
Kimberly A. Thompson et al, “Gonadotropin Requirements of the Developing Follicle”, Fertility and Sterility, 1995, vol. 63, pp. 273-276.
Uma Deve Gordon et al, “A Randomized Prospective Assessor-Blind Evaluation of Luteinizing Hormone Dosage and In Vitro Fertilization Outcome”, Fertility and Sterility, Feb. 2001, vol. 75, pp. 324-331.
Zeev Blumenfeld et al, “Early Pregnancy Wastage: The Role of Repetitive Human Chorionic Gonadotropin Supplementation During the First 8 Weeks of Gestation”, Fertility and Sterility, Jul. 1992, vol. 58, pp. 19-23.
M. Filicori et al, “Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome”, The Journal of Endocrinology and Metabolism, 1999, vol. 84, pp. 2659-2663.
W.R. Robertson et al, “the In Vitro bioassay of Peptide Hormones”, Peptide Hormones: a Practical Approach, IRL Press, Oxford, 1990, pp. 121-159.
Browdy and Neimark PLLC
Gupta Anish
Ha Julie
Laboratoires Seronosa
LandOfFree
Method for aiding implantation or decreasing miscarriage rate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for aiding implantation or decreasing miscarriage rate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for aiding implantation or decreasing miscarriage rate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965115